Multifaceted Secukinumab-induced Colitis

Inflamm Bowel Dis. 2022 Mar 30;28(4):e47-e48. doi: 10.1093/ibd/izab267.

Authors

Alexandros G Sykaras¹, Evangelia Margellou², Natalia G Vallianou², Fotis Panagopoulos², Eleni Geladari², Dimitris Kounatidis², Ioannis Alevizakis³, Christina Magkou¹

Affiliations

¹ Department of Pathology, Evangelismos Hospital, Ipsilantou 45-47, 106 46, Athens, Greece.
² Department of Internal Medicine, Evangelismos Hospital, Ipsilantou 45-47, 106 46, Athens, Greece.
³ Department of Surgery, Evangelismos Hospital, Ipsilantou 45-47, 106 46, Athens, Greece.

PMID: 34792606
DOI: 10.1093/ibd/izab267

No abstract available

Publication types

Case Reports

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / adverse effects
Colitis* / chemically induced
Female
Humans
Psoriasis*
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
secukinumab